BIORCHESTRA

BIORCHESTRA, with offices in Daejeon, South Korea, and Cambridge, Massachusetts, USA, is an innovative biotech developing ribonucleic acid (RNA) based therapeutics. The company's goal is to change the therapeutic paradigm from symptoms treatment to diseases modifying therapeutics in neurodegenerative and other diseases. The BMD is a therapeutic age... nt development platform that can control microRNAs that regulate multiple messenger RNAs (mRNAs) involved in pathological factors related to diseases. The company believes that exclusively targeting single pathological protein, such as A or tau, like most candidate AD therapies of other pharmaceutical companies is too late in the disease course to halt the progression of AD. This upstream regulation with anti-sense oligonucleotide aims to reverse the epigenetic changes in the AD brain induced by the overexpression of target microRNA-485-3p, which the company has proven to induce A/tau production, cognitive impairment and a reduction in synaptic plasticity. The company has developed proprietary drug delivery system (BDDS) for commercial drug development. Delivering the ASO via intravenous injection route, the company observed target microRNA knock-down efficacy not only in cortex but also deep brain such as hippocampus even striatum and spinal cord as well.Read More